Nicox

2024 Ordinary and Extraordinary Shareholder Meeting

Press Release

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting

April 9, 2024 – release at 17:30 CET Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary general meeting convened on first call on Wednesday April 10, 2024, will not be held as the quorum required by law has not been reached.

The shareholders of Nicox are thus convened on second call for an Ordinary and Extraordinary general meeting on the same resolutions and the same agenda on Monday May 6 at 2:30 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.



The documents relating to the general meeting, including the draft resolutions and the proxy form, are made available to shareholders at the headquarters of the Company and on its website (www.nicox.com).



Shareholders may vote by proxy, by internet or by attending the Ordinary and Extraordinary shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is posted on Nicox’s website. Shareholders may also contact the Company’s Investor Relations team at [e-mail] for any question on the voting process. The proxy forms sent by correspondence, or the electronic votes received for the Ordinary and Extraordinary general meeting initially planned on April 10, 2024 remain valid for the Ordinary and Extraordinary general meeting of May 6, 2024. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.